Clinical Trials Logo

Cancer clinical trials

View clinical trials related to Cancer.

Filter by:

NCT ID: NCT06415201 Recruiting - Cancer Clinical Trials

Interactive AI-based Mental Health Service for the Patients With Cancer

Start date: March 1, 2024
Phase:
Study type: Observational

The aims of this study are developments of mental health care services for cancer patients based on interactive artificial intelligence. To do these things, survey of unmet medical needs and data collection of clinical interviews will be done, and newly developed assessment and intervention scenarios will be simulated to cancer patients group.

NCT ID: NCT06414304 Recruiting - Cancer Clinical Trials

Dynamics of MSI and Genomic Profile of Colorectal Cancer In the Course of Immune Checkpoint Inhibitor Therapy

BLOOMSI
Start date: June 1, 2022
Phase:
Study type: Observational

Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide. Microsatellite instability or mismatch repair deficiency occurs in 20% of CRC, and is predominantly found in non-metastatic tumors. The success of the CheckMate 142 and KEYNOTE-177 clinical trials has shifted the treatment paradigm of the MSI/dMMR CRC, which has led to the adoption of immune checkpoint inhibitors (ICI) by international treatment standards. However, despite the encouraging effects of ICI, up to 30% of patients are resistant to treatment and exhibit rapid disease progression shortly after starting ICI. On the other hand, around 30% of patients treated with ICI demonstrate prolonged responses to the treatment with a duration of response of over 40 months. Furthermore, for ~10% of patients, treatment with ICI results in pseudo-progression - a phenomenon of a short-term increase followed by the decrease of the tumor volume. Currently, the mechanisms and biomarkers associated with the response or resistance to ICI in MSI-positive CRC are largely unknown. Select studies suggest that BRAF mutations (specifically, BRAF p.V600E) might negatively affect the patients' progression-free survival following ICI, however, these data are premature. The primary hypothesis is that the clonal heterogeneity and the evolution of MSI status of MSI-positive CRC will play a role in the development of ICI treatment resistance. The primary objective of the study is to investigate the dynamics of MSI status in serial liquid biopsy samples from patients with MSI-positive tumors receiving ICI.

NCT ID: NCT06409065 Recruiting - Cancer Clinical Trials

Psycho-Spiritual Management for Patients With Advanced Cancer and Their Family Caregivers

Start date: January 9, 2024
Phase: N/A
Study type: Interventional

The goal of this behavioral research study is to learn about the effects of two different supportive care programs on patients' and their family caregivers' psychological wellbeing and overall quality of life.

NCT ID: NCT06403436 Recruiting - Cancer Clinical Trials

A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors

TT-CSP-001
Start date: November 7, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety and therapeutic effect of TT125-802 (single agent) in subjects with advanced solid tumors.

NCT ID: NCT06393569 Recruiting - Cancer Clinical Trials

Sense of Security With Access to Palliative Outpatient Clinic

Start date: March 14, 2024
Phase:
Study type: Observational

The aim of the study is to evaluate experience of security, accessibility, and avoidable utilization of health care services in patients who have had access to specialized palliative care clinic (SPCC) compared to those who have not, and to evaluate the relatives' experience of the care.

NCT ID: NCT06381024 Recruiting - Cancer Clinical Trials

A Study of Telemonitoring in Cancer Patients

MINERVA
Start date: April 4, 2023
Phase: N/A
Study type: Interventional

The goal of this prospective, randomized, unblinded, single-centre, interventional study is to assess the effectiveness of standard of care with Cureety, compared to standard of care alone, to reduce the number of all telephone calls during the first 4 months of oral or intravenous cancer treatment for patients older than 18 years of age, initiating oral or intravenous cancer treatment at the Centre Hospitalier de Bligny. Patients initiating either oral or intravenous chemotherapy for cancer will be randomly allocated in a 1:1 ratio to either: - In-person care alone (Standard of care group). - In-person care with Cureety telemonitoring (Standard of care with Cureety group). Participants will: - be monitored with digital application Cureety (Standard of care with Cureety group) - fill out quality of life questionnaire (baseline, 2 months, 4 months) - fill out satisfaction questionnaire (2 months, 4 months) - have the ongoing and incoming phone calls logged (duration and type)

NCT ID: NCT06377202 Recruiting - Cancer Clinical Trials

Long-Term Follow-Up Safety Study of Subjects Treated With SynKIR-110 in Cancer Studies

Start date: November 15, 2023
Phase:
Study type: Observational

The primary objective of this study is to evaluate the long-term safety of SynKIR- 110 administered to adult subjects with solid tumors expressing mesothelin.

NCT ID: NCT06368947 Recruiting - Cancer Clinical Trials

Therapeutic Play on Pain Tolerance and Emotion Regulation in Children

Start date: March 29, 2024
Phase: N/A
Study type: Interventional

The research is a randomized controlled experimental study. The population of the research will consist of 10-18 year old children who were diagnosed with acute lymphoblastic leukemia and received chemotherapy, who were admitted to the Children's Hematology Clinic of Adana City Training and Research Hospital between 19.05.2024 and 19.05.2025. Therapeutic play sessions will occur over a 4-week period during chemotherapy treatment.

NCT ID: NCT06367959 Recruiting - Cancer Clinical Trials

Health Benefits of Writing Therapy Among Asian American Cancer Survivors

Start date: July 27, 2023
Phase: N/A
Study type: Interventional

To learn more about participant experience as a Asian American immigrant breast cancer survivor and how writing about participant experiences may affect participant's health.

NCT ID: NCT06361862 Recruiting - Cancer Clinical Trials

Does Continuous Vital Sign Monitoring Increase Investigations and Interventions in Complication-free Patients?

WARD-OT
Start date: January 1, 2024
Phase: N/A
Study type: Interventional

This aim of this study is to investigate whether active alerts during CVSM result in an increased number of diagnostic tests and treatments in complication free patients, hypothesizing that more interventions are performed in the CVSM-group than standard of care (EWS) group.